Cargando…

Corrigendum to: Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032293/ https://www.ncbi.nlm.nih.gov/pubmed/36880433 http://dx.doi.org/10.1093/ijnp/pyad007

Ejemplares similares

Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia
por: Goldstein, Meghan Elizabeth, et al.
Publicado: (2015)

Glutamatergic neurometabolite levels in the caudate are associated with the ability of rhythm production
por: Honda, Shiori, et al.
Publicado: (2023)

S16. GLUTAMATERGIC NEUROMETABOLITE LEVELS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA: A CROSS-SECTIONAL 3T PROTON MRS STUDY
por: Iwata, Yusuke, et al.
Publicado: (2018)

T212. LEVELS OF GLUTAMATERGIC NEUROMETABOLITES IN PATIENTS WITH SEVERE TREATMENT-RESISTANT SCHIZOPHRENIA: A PROTON MAGNETIC RESONANCE SPECTROSCOPY STUDY
por: Tarumi, Ryosuke, et al.
Publicado: (2020)

Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients
por: Hribkova, Hana, et al.
Publicado: (2022)

Glutamatergic Neurometabolites during Early Abstinence from Chronic Methamphetamine Abuse
por: O’Neill, Joseph, et al.
Publicado: (2015)

N-Acetyl and Glutamatergic Neurometabolites in Perisylvian Brain Regions of Methamphetamine Users
por: Tang, Jinsong, et al.
Publicado: (2018)

Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations [Corrigendum]
Publicado: (2019)

Antipsychotic medication for women with schizophrenia spectrum disorders – CORRIGENDUM
por: Brand, Bodyl A., et al.
Publicado: (2023)

Corrigendum to abnormalities in personal space and parietal–frontal function in schizophrenia
por: Holt, Daphne J., et al.
Publicado: (2016)

Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
por: James, Suneeta, et al.
Publicado: (2019)

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial – CORRIGENDUM
por: Dai, Minhan, et al.
Publicado: (2021)

Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies
por: Moriguchi, Sho, et al.
Publicado: (2018)

Autobiographical memory and default mode network function in schizophrenia: an fMRI study—CORRIGENDUM
por: Martin-Subero, Marta, et al.
Publicado: (2021)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]
Publicado: (2021)

Corrigendum to: Semantic Memory Impairment Across the Schizophrenia Continuum: A Meta-Analysis of Category Fluency Performance
por: Tan, Eric Josiah, et al.
Publicado: (2021)

Effectiveness of clozapine in treatment-resistant schizophrenia
por: Raguraman, Janakiraman, et al.
Publicado: (2005)

Management of patients with Clozapine Resistant Schizophrenia
por: Rajendran*, Nithya Ragavi, et al.
Publicado: (2022)

Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia
por: Tseng, Ping-Tao, et al.
Publicado: (2022)

Corrigendum: Fluid responsiveness in the pediatric population
por: Lee, Ji-Hyun, et al.
Publicado: (2019)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
Publicado: (2021)

Treatment Resistant Atopic Dermatitis: Challenges and Solutions [Corrigendum]
Publicado: (2019)

M215. FACTORS ASSOCIATED WITH CLOZAPINE RESPONSE AND RESISTANCE IN SCHIZOPHRENIA
por: Lee, Jimmy, et al.
Publicado: (2020)

Corrigendum to “Supporting the dying is a community responsibility”
Publicado: (2022)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

An international multi-site, randomized controlled trial of a mindfulness-based psycho-education group program for people with schizophrenia – CORRIGENDUM
por: Chien, W. T., et al.
Publicado: (2023)

Diversity and evolution of drug resistance mechanisms in Mycobacterium tuberculosis [Corrigendum]
Publicado: (2017)

Corrigendum to: Limited evolutionary conservation of multidrug resistance and collateral sensitivity
por: Apjok, Gábor, et al.
Publicado: (2021)

Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis [Corrigendum]
Publicado: (2022)

Glutamatergic dysfunction in Schizophrenia
por: Kruse, Andreas O., et al.
Publicado: (2022)

Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
por: Montgomery, Adam, et al.
Publicado: (2023)

A False Case of Clozapine-Resistant Schizophrenia
por: Maia-de-Oliveira, J. P., et al.
Publicado: (2010)

AN OPEN STUDY OF CLOZAPINE IN THE TREATMENT OF RESISTANT SCHIZOPHRENIA
por: Desai, Neena, et al.
Publicado: (1999)

Combination of ECT and clozapine in drug-resistant schizophrenia
por: Kurian, S., et al.
Publicado: (2005)

Clozapine resistant schizophrenia: Newer avenues of management
por: Chakrabarti, Subho
Publicado: (2021)

Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]
Publicado: (2016)

Corrigendum to “Circulating Endocannabinoids and Insulin Resistance in Patients with Obstructive Sleep Apnea”
por: Wang, Xiaoya, et al.
Publicado: (2018)

Corrigendum: Antimicrobial resistance surveillance in Ethiopia: Implementation experiences and lessons learned
por: Ibrahim, Rajiha A., et al.
Publicado: (2019)

Corrigendum to“Resistive index as a predictor of early failure of kidney transplantation”
por: Jeong, Dai Sik, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hlsoicerfa08fgvuu1s12tiq2d